News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s
A provider can then review both your peptide pathway variants and clinical history together, supporting a more personalized treatment strategy beyond cost alone
Grabner, G
How can PlexusDx's Precision Peptide Genetic Test help me understand my GLP-1 treatment needs
Heavy drinking should be discussed with your provider regardless
Melanin Boost: Known for its effects on melanin production, Melanotan-II helps encourage a sun-kissed complexion while minimizing sun damage risks